These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 21909830)

  • 21. Long-term outcomes after transoral incisionless fundoplication in patients with GERD and LPR symptoms.
    Trad KS; Turgeon DG; Deljkich E
    Surg Endosc; 2012 Mar; 26(3):650-60. PubMed ID: 21959689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endotherapy for and tailored approaches to treating GERD, and refractory GERD.
    Locke GR; Horwhat J; Mashimo H; Savarino E; Zentilin P; Savarino V; Zerbib F; Armbruster SP; Wong RK; Moawad F
    Ann N Y Acad Sci; 2013 Oct; 1300():166-186. PubMed ID: 24117641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do endoscopic antireflux procedures fit in the current treatment paradigm of gastroesophageal reflux disease?
    Pandolfino JE; Krishnan K
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):544-54. PubMed ID: 23811248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical outcome in gastro-esophageal reflux disease patients with inadequate response to proton pump inhibitors.
    Anvari M; Allen C
    Surg Endosc; 2003 Jul; 17(7):1029-35. PubMed ID: 12728384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antireflux Surgery in Korea: A Nationwide Study from 2011 to 2014.
    Lee JH; Park JM; Han SU; Kim JJ; Song KY; Ryu SW; Seo KW; Kim HI; Kim W;
    Gut Liver; 2016 Sep; 10(5):726-30. PubMed ID: 27114420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and future perspectives in the management of gastroesophageal reflux disease.
    Akiyama J; Kuribayashi S; Baeg MK; de Bortoli N; Valitova E; Savarino EV; Kusano M; Triadafilopoulos G
    Ann N Y Acad Sci; 2018 Dec; 1434(1):70-83. PubMed ID: 29766521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus.
    Baldaque-Silva F; Vieth M; Debel M; Håkanson B; Thorell A; Lunet N; Song H; Mascarenhas-Saraiva M; Pereira G; Lundell L; Marschall HU
    World J Gastroenterol; 2017 May; 23(17):3174-3183. PubMed ID: 28533674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Borderline indications and selection of gastroesophageal reflux disease patients: 'Is surgery better than medical therapy'?
    Lundell L
    Dig Dis; 2014; 32(1-2):152-5. PubMed ID: 24603401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proton pump inhibitors in the management of GERD.
    Katz PO; Zavala S
    J Gastrointest Surg; 2010 Feb; 14 Suppl 1():S62-6. PubMed ID: 19774429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease.
    Kierkus J; Oracz G; Korczowski B; Szymanska E; Wiernicka A; Woynarowski M
    Drug Saf; 2014 May; 37(5):309-16. PubMed ID: 24706290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current aspects of surgical treatment of gastro-esophageal reflux disease].
    Danilova DA; Bazaev AV; Gorbunova LI
    Khirurgiia (Mosk); 2020; (2):89-94. PubMed ID: 32105262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term cost-effectiveness of medical, endoscopic and surgical management of gastroesophageal reflux disease.
    Funk LM; Zhang JY; Drosdeck JM; Melvin WS; Walker JP; Perry KA
    Surgery; 2015 Jan; 157(1):126-36. PubMed ID: 25262216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm.
    Trad KS; Fox MA; Simoni G; Shughoury AB; Mavrelis PG; Raza M; Heise JA; Barnes WE
    Surg Endosc; 2017 Jun; 31(6):2498-2508. PubMed ID: 27655380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
    Gyawali CP
    Curr Gastroenterol Rep; 2017 Sep; 19(9):46. PubMed ID: 28780717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease.
    Watson TJ; Peters JH
    Thorac Surg Clin; 2005 Aug; 15(3):405-15. PubMed ID: 16104131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of the traditional surgical procedures for gastroesophageal reflux disease cannot be ignored].
    Zhou JH; Tan QY
    Zhonghua Wai Ke Za Zhi; 2020 Sep; 58(9):672-676. PubMed ID: 32878412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Community-dwelling older adults' awareness of the inappropriate use of proton pump inhibitors.
    Rababa M; Rababa'h A
    BMC Geriatr; 2020 Oct; 20(1):431. PubMed ID: 33121444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Quality of Life Outcomes Following Nissen Versus Toupet Fundoplication in Patients with Gastroesophageal Reflux Disease.
    Gunter RL; Shada AL; Funk LM; Wang X; Greenberg JA; Lidor AO
    J Laparoendosc Adv Surg Tech A; 2017 Sep; 27(9):931-936. PubMed ID: 28737451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fundoplication versus oral proton pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis of randomized clinical trials.
    Tristão LS; Tustumi F; Tavares G; Bernardo WM
    Esophagus; 2021 Apr; 18(2):173-180. PubMed ID: 33527310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.